Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Bull ME, McKernan JL, Styrchak S, Kraft K, Hitti J, Cohn SE, Tapia K, Deng W, Holte S, Mullins JI, Coombs RW, Frenkel LM.

AIDS Res Hum Retroviruses. 2019 Jun;35(6):557-566. doi: 10.1089/AID.2018.0211. Epub 2019 Apr 30.

PMID:
30892052
2.

Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.

Bull ME, Mitchell C, Soria J, Styrchak S, Williams-Wietzikoski C, Legard J, McKernan-Mullin J, Kraft K, Onchiri F, Stern J, Holte S, Ryan KJ, Acosta EP, La Rosa A, Coombs RW, Ticona E, Frenkel LM.

AIDS. 2018 Jul 17;32(11):1389-1401. doi: 10.1097/QAD.0000000000001824.

3.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

4.

Comparison of Matrix-Based and Filter Paper-Based Systems for Transport of Plasma for HIV-1 RNA Quantification and Amplicon Preparation for Genotyping.

Levine M, Beck I, Styrchak S, Pepper G, Frenkel L.

J Clin Microbiol. 2016 Jul;54(7):1899-1901. doi: 10.1128/JCM.00541-16. Epub 2016 Apr 13.

5.

Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy.

Ticona E, Bull ME, Soria J, Tapia K, Legard J, Styrchak SM, Williams C, Mitchell C, La Rosa A, Rosa AL, Coombs RW, Frenkel LM.

AIDS. 2015 Aug 24;29(13):1617-22. doi: 10.1097/QAD.0000000000000758. Erratum in: AIDS. 2015 Sep 24;29(15):2065. Rosa, Alberto L A [corrected to La Rosa, Alberto].

6.

HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection.

Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM.

Science. 2014 Aug 1;345(6196):570-3. doi: 10.1126/science.1256304. Epub 2014 Jul 10.

7.

Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.

Mullins JI, Heath L, Hughes JP, Kicha J, Styrchak S, Wong KG, Rao U, Hansen A, Harris KS, Laurent JP, Li D, Simpson JH, Essigmann JM, Loeb LA, Parkins J.

PLoS One. 2011 Jan 14;6(1):e15135. doi: 10.1371/journal.pone.0015135.

8.

KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.

Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R.

Antiviral Res. 2005 Jul;67(1):1-9.

PMID:
15890415

Supplemental Content

Loading ...
Support Center